Trial Profile
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of daily oral administration of 5mg and 10mg Vesicare for the treatment of urgency associated with overactive bladder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms VENUS
- Sponsors Astellas Pharma
- 12 Jun 2007 New trial record.